By Michael Susin

AstraZeneca said late Friday that interim analysis of the phase III study regarding its Imfinzi drug together with chemotherapy significantly improved pathologic complete response in gastric and gastroesophageal junction cancers.

The Anglo-Swedish pharma giant said that the trial demonstrated a statistically significant and clinically meaningful improvement in the key secondary endpoint of pathologic complete response in patients with resectable, early-stage and locally advanced gastric and gastroesophageal junction cancers.

The company said that the trial will continue as planned to assess overall survival data.

Write to Michael Susin at michael.susin@wsj.com

(END) Dow Jones Newswires

June 02, 2023 12:28 ET (16:28 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Set 2023 a Ott 2023 Clicca qui per i Grafici di Astrazeneca
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Ott 2022 a Ott 2023 Clicca qui per i Grafici di Astrazeneca